Skip to main content
Bloomberg Law

How Life Sciences Firms Can Reduce DOJ Enforcement Risks

May 6, 2021
Authors
Jaime L.M. JonesJack W. Pirozzolo

The Anti-Kickback Statute has long been a driver of enforcement actions against the life sciences industry. In this article, Sidley lawyers explore areas that are most likely to draw enforcement scrutiny and how compliance programs can be updated to control risk going forward.

View Article

Contacts

Jones, Jaime L.M.
合伙人律师
Pirozzolo, Jack W.
合伙人律师

Related Blogs

Capabilities

Suggested News & Insights

DOJ Announces Accelerated Review of FCA Qui Tams Alleging Fraud Against State-Administered Benefits ProgramsMay 28, 2026
Original Source
Sidley Lawyers Jaime Jones, Jennifer Saulino, and Lisa Miller to Speak at the ABA′s 2026 Qui Tam & Civil False Claims and Healthcare Fraud Institute in Washington, D.C.Wednesday, May 27, 2026 – Thursday, May 28, 2026
活动
DOJ and Texas AG Announce First Settlement in National Investigation of Gender-Affirming Care for MinorsMay 26, 2026
Original Source
Vice President and CMS Announce Suite of New Administrative Actions to Further Federal Anti-Fraud Health Care InitiativesMay 20, 2026
Original Source
Tariff Enforcement at the Forefront: Importer Agrees to Pay $549.5 million in Largest-Ever Trade-Related False Claims Act SettlementMay 18, 2026
Original Source
The First Prediction Market Insider Trading Case: SDNY and CFTC Test the Limits of Fraud and Commodities LawMay 13, 2026
White Collar Defense and Investigations Update